Vitamin B12 Cream for Eczema: What the Split-Body Trials Show

The B12 eczema trials compared opposite sides of each participant’s body. Their findings concern particular creams, rather than every B12 product.

The eight-week trial compared cream with its base

The 2004 German trial¹ randomized 49 adults; 41 completed it according to protocol. Participants applied 0.07% cyanocobalamin cream twice daily for eight weeks, with a matching base cream on the opposite side. Their eczema was chronic, without acute inflammation or superinfection.¹

The modified SASSAD severity score fell by 55.34 points with B12 versus 28.87 with placebo (P<0.0002). These are score changes, not percentages of people cured. Regeneratio Pharma supported the study. Skin irritation possibly or probably related to the B12 cream occurred, despite the report’s generally favorable tolerability assessment.¹

This cream-base comparison cannot establish equivalence to a prescribed corticosteroid or justify stopping it.

The later barrier cream contained more than B12

The 2017 single-blind study² enrolled 22 White adults with mild atopic dermatitis. One side received a 0.07% cyanocobalamin barrier cream containing 1% urea; the other received a glycerol-petrolatum emollient. Treatment lasted twelve weeks, followed by a four-week assessment after stopping.²

Its abstract reports 77.6% versus 33.5% reductions in SCORAD, another eczema severity measure. The discussion instead gives 80% versus 15% for the same baseline-to-week-twelve interval. Both descriptions favor the B12 cream, but that inconsistency makes a precise percentage claim unreliable.²

This was also a comparison of two formulations. Because the B12 product included urea and a different carrier system, the study cannot assign its entire advantage to the vitamin alone. Its mild-disease population does not establish treatment for severe eczema.²

The childhood study was short and small

The 2009 double-blind trial³ recruited children aged six months to 18 years; 21 completed four weeks. It also compared opposite sides of the same child. Skin scores improved more on the B12-treated side at two weeks (P=0.02) and four weeks (P=0.01).³

That result supports further investigation. A four-week study with 21 completers cannot establish long-term safety, prevention of future flares or the best regimen for a particular child’s age and affected skin area.

Where this leaves a treatment decision

The AAD’s current adult guidelines strongly recommend moisturizers and established topical treatments, including corticosteroids, calcineurin inhibitors, PDE-4 inhibitors and JAK inhibitors. Its 2025 update adds newer treatments. For eczema that resists optimized treatment, the Academy also supports considering whether the diagnosis needs reassessment.⁴

The AAD’s separate patient page on vitamins acknowledges a positive adult B12 cream study but says the evidence is insufficient to recommend vitamins or minerals for eczema. Its brief summary is not a complete list of the trials above. It advises discussing additions to a child’s treatment with their dermatologist.⁵

Bring the complete cream ingredient list, current prescriptions and the outcome you want to change: itch, sleep interruption or the extent of inflamed skin. Ask whether the formulation has evidence relevant to your eczema and how any supervised trial would fit your existing plan. These skin-application studies do not test swallowing B12 tablets.

Chapter 5’s “The Barrier, and the Three Jobs a Moisturizer Does” in Skin, Head to Toe explains why the cream base deserves attention alongside a featured ingredient. Our adult eczema guide covers the broader diagnosis and treatment discussion.